IP Library › Granted Patent US 12,511,755
Granted Patent B2
US 12,511,755 · App. 19/199,038 · Granted Dec 30, 2025

Method for reconfiguring ultrasound

Inventors: Andrew John Healey (Moss, NO); Svein Kvåle (Ås, NO); Ola Myhre (Haslum, NO)
Assignee: EXACT THERAPEUTICS AS
G06T7/11G06T7/0012G06T2207/10081G06T2207/10088G06T2207/10132G06T2207/30008G06T2207/30024G06T2207/30104
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,511,755
App. No.
19/199,038
Granted
Dec 30, 2025
Kind
B2
Abstract

A method and related systems for refiguring an ultrasound dose are described. The method may involve creating a medium property map of a region of interest of a subject, wherein the medium property map provides different medium property values in different segments of the region of interest dependent on the medium within each segment. The method may further involve obtaining an image of the region of interest, including a target treatment area and a surrounding region of the target treatment area. In some cases, the method includes processing the image to identify different components of the region of interest, segmenting and categorizing the different components into predetermined media categories, and retrieving a medium property value associated with each media category. The medium property value may be attributed to each respective component of the segmented region of interest.

Claims (77)

1 . A method for reconfiguring an ultrasound source that provides an ultrasound dose, the method comprising:

calculating a unique ultrasound propagation correction factor for a specific ultrasound propagation path through a particular region of interest by:

creating a medium property map of the region of interest, wherein the medium property map provides a plurality of different medium property values in different segments of the region of interest dependent on a medium within each of said segments, comprising:

scanning an image of the region of interest, wherein the region of interest comprises a target treatment area and a surrounding region of the target treatment area;

processing, by an image processor, the image to identify different components of the region of interest; and

segmenting and categorizing the different components into predetermined media categories;

calculating a medium property value associated with each media category, comprising:

retrieving a standard medium property value associated with each media category from a database;

estimating a category-specific ultrasound coupling bubble element correction to the standard medium property value resulting from presence of at least one ultrasound coupling bubble element in at least one component; and

adjusting the medium property value of the at least one component to account for the respective category-specific ultrasound coupling bubble element correction;

attributing said medium property value to each respective component of the segmented region of interest;

delineating the propagation path from an ultrasound source to the target treatment region;

compiling the medium property values for each segment over the propagation path to calculate the unique propagation correction factor; and

using the unique propagation correction factor to indicate a delivered ultrasound dose delivered to the target treatment area; and

reconfiguring the ultrasound source that provides the ultrasound dose in view of the delivered ultrasound dose.

2 . The method of claim 1 , wherein the media categories comprise at least one of the group consisting of:

different tissue types;

different tissue types afflicted by one or more particular diseases;

a fluid; and

a gas.

3 . The method of claim 2 , wherein the different tissue types comprise one or more of the group consisting of:

soft tissue comprising fat, muscle, parenchyma, tendons and ligaments; and

hard tissue comprising bone.

4 . The method of claim 1 , wherein the image scan comprises one or more of the group consisting of:

a computer tomography image; and

a magnetic resonance image.

5 . The method of claim 1 , wherein the at least one ultrasound coupling bubble element comprises one or more of the group consisting of:

contrast agent microbubbles;

cavitation seeds;

large microbubbles;

acoustic cluster therapy (ACT) bubble technology ultrasound coupling bubble elements, wherein the ACT bubble technology ultrasound coupling bubble elements comprise:

ACT microbubble clusters; and

activated ACT bubbles.

6 . The method of claim 5 , wherein the at least one ultrasound coupling bubble element comprises contrast agent microbubbles and wherein estimating a contrast agent microbubble correction comprises:

retrieving or estimating contrast agent microbubble parameters, wherein the contrast agent microbubble parameters comprise:

a value for a dose of contrast agent microbubbles administered;

contrast agent attenuation per unit concentration;

a blood volume of a subject;

a cardiac output of the subject;

a value of blood volume associated with each category;

arrival times after intravenous administration of the contrast agent for each category; and

a time concentration curve; and

using the contrast agent parameters to calculate a contrast agent correction for each category.

7 . The method of claim 6 , wherein calculating the correction resulting from the presence of contrast agent in each category is based on contrast mode imaging ultrasound.

8 . The method of claim 5 , wherein the at least one ultrasound coupling bubble element comprises ACT bubble technology ultrasound coupling bubble elements and wherein calculating an additional ACT bubble correction comprises:

estimating additional correction resulting from ACT microbubble clusters in the presence of the high frequency activation ultrasound;

estimating additional correction resulting from generated ACT bubbles in the presence of high frequency activation ultrasound; and

estimating additional correction resulting from ACT bubbles in the presence of low frequency enhancement ultrasound.

9 . The method of claim 8 , wherein calculating additional ACT bubble correction further comprises:

estimating a number of ACT bubbles in the categories associated with each component by:

retrieving or estimating one or more ACT bubble parameters, wherein the ACT bubble parameters comprise:

a blood volume of a subject;

a cardiac output of the subject;

a perfusion of each category of components; and

a time concentration curve; and

calculating the number of ACT bubbles delivered to each of the components by multiplying a fraction of the cardiac output that accounts for the perfusion of each category of components by a yield of activation of ACT bubble clusters.

10 . The method of claim 9 , wherein the estimation of the number of ACT bubbles in the categories associated with each segment comprise a time dependency by:

retrieving a value for a lifetime of an ACT bubble in each category to model a reduction of the number of ACT bubbles in each category over time.

11 . The method of claim 8 , wherein calculating the additional correction resulting from the presence of ACT bubbles in each category is based on fundamental B-mode imaging ultrasound.

12 . The method of claim 1 , further comprising using the unique propagation correction factor to calculate at least one of the group consisting of: a resulting pressure, a resulting mechanical index, a resulting intensity, a resulting power and a resulting thermal index, which are indications of delivered ultrasound dose.

13 . The method of claim 1 , wherein the image processor segments and categorizes the different components of the region of interest by:

identifying boundaries between different patterns of the image;

analyzing the pattern within the boundaries; and

comparing each of the patterns to image patterns of known tissue type to find a match.

14 . The method of claim 13 , wherein the method is a machine learning method, comprising, for wherein accumulating each processed image, along with associated image data, as training data to provide more accurate segmentation and categorization by the image processor over time.

15 . The method of claim 1 , further comprising:

tracking an ultrasound probe's position, the ultrasound probe connected to the ultrasound source;

re-evaluating one or more propagation correction factors with movement of the probe position; and

storing one or more propagation correction factors per probe position to reduce a computational load.

16 . The method of claim 1 , further comprising:

tracking an in-plane and out-of-plane rhythmic movement of the medium of the region of interest;

re-evaluating one or more propagation correction factors for each in-plane and out-of-plane position of the moving medium; and

storing the one or more propagation correction factors for each in-plane and out-of-plane position of the moving medium.

17 . The method of claim 16 , further comprising tracking the in-plane and out-of-plane rhythmic movement of the medium through speckle-tracking or machine learning algorithms.

18 . The method of claim 1 , wherein the medium property comprises at least one of the group consisting of: attenuation, sound speed, shear wave velocity, acoustic impedance, coefficients of non-linear compressibility, and coefficients of dispersion.

19 . The method of claim 18 , wherein the medium property further comprises one or more derived properties that can be derived from any one, or any combination, of the medium properties listed.

20 . A non-transitory computer-readable storage medium, the computer-readable storage medium having stored thereon instructions that when executed on a processor perform the method of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: HEALEY, ANDREW JOHN; KVALE, SVEIN; MYHRE, OLA
To: EXACT THERAPEUTICS AS
Reel/Frame 071414/0681 →
Continuity (2)
Continuation PCTNO2023060084 · Nov 3, 2023
Related Publication 20250272845A1 · Aug 28, 2025
References Cited (100)
US 9629610B2 · Sandstrom · 2017 [cited by examiner]
US 12343396B2 · Healey et al. · 2025 [cited by applicant]
US 12377146B2 · Healey et al. · 2025 [cited by applicant]
US 20040081623A1 · Eriksen et al. · 2004 [cited by applicant]
US 20060025756A1 · Francischelli et al. · 2006 [cited by applicant]
US 20070178047A1 · Kawabata · 2007 [cited by applicant]
US 20080299084A1 · Brahmbhatt et al. · 2008 [cited by applicant]
US 20090252773A1 · Yoneda et al. · 2009 [cited by applicant]
US 20100298709A1 · Needles et al. · 2010 [cited by applicant]
US 20120165665A1 · Sandstrom · 2012 [cited by examiner]
US 20160243234A1 · Healey et al. · 2016 [cited by applicant]
US 20180200196A1 · Fahmy et al. · 2018 [cited by applicant]
US 20190216478A1 · Maxwell et al. · 2019 [cited by applicant]
US 20200254285A1 · Jang et al. · 2020 [cited by applicant]
US 20200323515A1 · Levy · 2020 [cited by applicant]
US 20200405258A1 · Dayton et al. · 2020 [cited by applicant]
US 20210299256A1 · Healey et al. · 2021 [cited by applicant]
US 20220378692A1 · Sontum et al. · 2022 [cited by applicant]
US 20230211020A1 · Kvale et al. · 2023 [cited by applicant]
US 20230218759A1 · Healey et al. · 2023 [cited by applicant]
US 20230218760A1 · Healey et al. · 2023 [cited by applicant]
US 20230233681A1 · Healey et al. · 2023 [cited by applicant]
US 20230241216A1 · Healey et al. · 2023 [cited by applicant]
US 20240216549A1 · Sontum et al. · 2024 [cited by applicant]
US 20240269489A1 · Kvåle et al. · 2024 [cited by applicant]
US 20240358984A1 · Kvåle et al. · 2024 [cited by applicant]
US 20240359037A1 · Sontum et al. · 2024 [cited by applicant]
US 20250235536A1 · Kvåle et al. · 2025 [cited by applicant]
CN 108815725A · 2018 [cited by applicant]
EP 0727225A3 · 1997 [cited by applicant]
EP 1842560 · 2007 [cited by applicant]
EP 2468191A1 · 2012 [cited by applicant]
EP 2521593B1 · 2012 [cited by applicant]
EP 2468191B1 · 2019 [cited by examiner]
JP 2005168312 · 2005 [cited by applicant]
JP 2007197403 · 2007 [cited by applicant]
JP 2008526785 · 2008 [cited by applicant]
WO WO1994016379A1 · 1994 [cited by applicant]
WO WO1998001732A1 · 1998 [cited by applicant]
WO WO1998017324 · 1998 [cited by applicant]
WO WO1998051284A1 · 1998 [cited by applicant]
WO WO1999039738 · 1999 [cited by applicant]
WO WO1999053963A1 · 1999 [cited by applicant]
WO WO1999053965 · 1999 [cited by applicant]
WO WO2005063306 · 2005 [cited by applicant]
WO WO2015047103 · 2015 [cited by applicant]
WO WO2017080481 · 2017 [cited by applicant]
WO WO2018126322 · 2018 [cited by applicant]
WO WO2019094802 · 2019 [cited by applicant]
WO WO2020115491 · 2020 [cited by applicant]
WO WO2021045485 · 2021 [cited by applicant]
WO WO2021080438 · 2021 [cited by applicant]
WO WO2021118783 · 2021 [cited by applicant]
WO WO2021224921 · 2021 [cited by applicant]
WO WO2022069377 · 2022 [cited by applicant]
Andersen et al., “A harmonic dual-frequency transducer for acoustic cluster therapy.” Ultrasound Med Biol. Sep. 1, 2019;45(9):2381-2390. [cited by applicant]
Aoki et al., “Image of tumor matastasis and inflammatory lymph node enlargement by contrast-enhanced ultrasonography,” Word Journal of Radiology, Dec. 28, 2011, pp. 298-305. [cited by applicant]
Argenziano et al., Vancomycin-loaded nanobubbles: A new platform for controlled antibiotic delivery against methicillin-resistant [cited by applicant]
Åslund et al., “Efficient Enhancement of Blood-Brain Barrier Permeability Using Acoustic Cluster Therapy (ACT)”, Theranostics 2017, vol. 7, Issue 1, doi: 10.7150/thno. 16577. [cited by applicant]
Beccaria et al., “Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits,” Journal of Neurosurgery, vol. 124, No. 6, Jun. 1, 2016, pp. 160… [cited by applicant]
Brighi, “MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma,” Neuro-Oncology Advances, vol. 2, No. 1, Mar. 5, 2020 in 12 pages. [cited by applicant]
Bulner et al., “Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles,” Ultrasound in Medicine and Biology, vol. 45, No. 2, Nov. 15, 2018, pp. 500-512. [cited by applicant]
Bush et al., “Acoustic Cluster Therapy displays theranostic capability in enhancing the effectiveness of liposomal doxorubicin treatment of human triple negative breast cancer in mice,” In 2019 IEEE International Ultras… [cited by applicant]
Bush et al., “Ultrasound, optical and photoacoustic imaging of Acoustic Cluster Therapy enhanced delivery to human tumors in mice,” In 2019 IEEE International Ultrasonics Symposium [IUS], Oct. 6, 2019, pp. 1556-1559. [cited by applicant]
Bush et al., “Therapeutic Dose Response of Acoustic Cluster Therapy in Combination With Irinotecan for the Treatment of Human Colon Cancer in Mice,” Front Pharmacol. Nov. 19, 2019;10:1299 in 14 pages. [cited by applicant]
Bush et al., “Theranostic Attributes of Acoustic Cluster Therapy and Its Use for Enhancing the Effectiveness of Liposomal Doxorubicin Treatment of Human Triple Negative Breast Cancer in Mice,” Front Pharmacol. Feb. 20, … [cited by applicant]
Carpentier et al., “Clinical trial of blood-brain barrier disruption by pulsed ultrasound,” Science Translational Medicine, vol. 8, No. 343, Jun. 15, 2016 in 8 pages. [cited by applicant]
Carter et al., “Immune-oncology agents for cancer therapy.” Pharm. J. May 2020;304(7937): S2-S27. [cited by applicant]
Castle et al., “Ultrasound-mediated targeted drug delivery: recent success and remaining challenges”. Am J Physiol Heart Circ Physiol. Feb. 2013;304(3):H350-7. [cited by applicant]
Chen et al., “Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study,” Journal of Translational Medicine, vol. 13, No. 1,… [cited by applicant]
Chen et al., “Theranostic Strategy of Focused Ultrasound Induced Blood-Brain Barrier Opening for CNS Disease Treatment,” Frontiers in Pharmacology, vol. 10, Feb. 7, 2019 in 14 pages. [cited by applicant]
Curley et al., “Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities,” Theranostics, vol. 7, No. 15, Jan. 1, 2017, pp. 3608-3623. [cited by applicant]
Dimcevski et al., “A human clinical trial using ultrasound and microbubbles to enhance gemcitabinetreatment of inoperable pancreatic cancer”, J Control Release, 2016, vol. 243, pp. 172-181, http://dx.doi.org/10.1016/j.j… [cited by applicant]
Goldwirt et al., “Enhanced brain distribution of carboplatin in a primate model after blood-brainbarrier disruption using an implantable ultrasound device,” Cancer Chemotherapy and Pharmacology, Springer Verlag, vol. 77… [cited by applicant]
Healey et al. “Acoustic cluster therapy: in vitro and ex vivo measurement of activated bubble size distribution and temporal dynamics,” Ultrasound in Med Biol. May 1, 2016;42(5):1145-6611. [cited by applicant]
Jordao et al., “Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-? Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease,” PLOS ONE, vol. 5, No. 5, May 1, 2010 in 8 pages. [cited by applicant]
Kinoshita et al., “Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound,” Biochemical and Biophysical Research Communications, vol. 340, No. 4, Feb. 24, 2006, pp. 1085-1090. [cited by applicant]
Kooiman et al. Ultrasound-responsive cavitation nuclei for therapy and drug delivery. Ultrasound Med Biol. Jun. 1, 2020;46(6):1296-1325. [cited by applicant]
Kotopoulis, et al., “Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma”, J Control Release, Nov. 2026; 245:… [cited by applicant]
Kurdziel et al., “Human dosimetry and preliminary tumour distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT”. J Nucl Med. Sep. 1, 2011;52(9):1339-1345. [cited by applicant]
Lattwein et al., Sonobactericide: an emerging treatment strategy for bacterial infections. Ultrasound Med Biol. Feb. 1, 2020;46(2):193-215. [cited by applicant]
Mainprize et al., “Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study,” Scientific Reports, vol. 9, No. 1, Dec. 1, 2019 in 7 pages. [cited by applicant]
Miller et al., “Bioeffects Considerations for Diagnostic Ultrasound Contrast Agents”, Journal of Ultrasound Med 2008; vol. 27, pp. 611-632. [cited by applicant]
Ng et al., “Abstract A099: Acoustic Cluster Therapy enhances the efficacy of chemotherapeutic regimens in patient-derived xenograft mouse models for pancreatic ductal adenocarcinoma,” Molecular Cancer Therapeutics, vol.… [cited by applicant]
Postema et al., “Contrast-enhanced and Targeted Untrasound”, World Journal of Gastroenterol, Jan. 7, 2022, vol. 17, pp. 28-41. [cited by applicant]
Ryman et al., “Pharmacokinetics of monoclonal antibodies”. CPT Pharmacometrics Syst Pharmacol. Sep. 2017;6(9):576-588. [cited by applicant]
Schultz et al., “Selecting the Optimal Parameters for Sonoporation of Pancreatic Cancer in a Pre-Clinical Model,” 2019 IEEE International Ultrosonics Symposium (IUS), IEEE, Oct. 6, 2019 (Oct. 6, 2019), pp. 328-331, XP03… [cited by applicant]
Sontum et al., “Acoustic Cluster Therapy (ACT)—A novel concept for ultrasound mediated, targeted drug delivery.” Int J Pharma. Nov. 30, 2015;495(2):1019-1027. [cited by applicant]
Sontum et al., “Acoustic Cluster Therapy—A Novel Approach for Ultrasound Mediated Targeted Drug Delivery: Technology Basics and Proof of Concept”. In submitted to 21st European Symposium on Ultrasound Contrast Imaging, … [cited by applicant]
Timko et al., “Remotely triggerable drug delivery systems”, Adv Mater. Nov. 24, 2010;22(44): 4925-4943. [cited by applicant]
Van Wamel et al., “Acoustic Cluster Therapy (ACT): a novel concept for targeted drug delivery—In vivo Characteristics and Proof of Principle,” ResearchGate, Jan. 1, 2015; in 4 pages. [cited by applicant]
Van Wamel et al. “Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice”, J Control Rel. Aug. 28, 2016;236:15-21. [cited by applicant]
Van Wamel et al. “Acoustic Cluster Therapy (ACT)—pre-clinical proof of principle for local drug delivery and enhanced uptake,” Journal of Controlled Release, vol. 224, Jan. 13, 2016, pp. 158-164. [cited by applicant]
Van Wamel et al., Ultrafast microscopy imaging of acoustic clustere therapy bubbles: Activation and oscillation. Ultrasound in Med Biol. Sep. 1, 2022;48(9): 1840-1857. [cited by applicant]
Wang et al., “Experimental study of tumor therapy mediated by multimodal imaging based on a biological targeting synergistic agent,” Intl J Nanomed. Mar. 17, 2020: 1871-1888. [cited by applicant]
Wei et al., “Focused Ultrasound-Induced Blood-Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A preclinical Study,” PLOS ONE, vol. 8, No. 3, Mar. 1, 2013 in 10 pages. [cited by applicant]
Zhang et al., “Focused-ultrasound Mediated Anti-Alpha-Synuclein Antibody Delivery for the Treatment of Parkinson's Disease,” 2018 IEEE International Ultrasonics Symposium, Oct. 22, 2018, pp. 1-4. [cited by applicant]
Zheng et al., “Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma,” Nanomedicine, vol. 13, No. 3, Feb. 1, 2018, pp. 297-311. [cited by applicant]
International Search Report and Written Opinion received in PCT Application No. PCT/No. 2023/060084 mailed on Feb. 19, 2024 in 9 pages. [cited by applicant]
Zhang et al., “Acoustic Droplet Vaporization for Enhancement of Thermal Ablation by High Intensity Focused Ultrasound,” Acard Radiol. Sep. 2011;8(9): 1123-1132. [cited by applicant]